NEW YORK, Aug. 24 (GenomeWeb News) - Icoria will identify biomarkers of toxicity in animal models for Isis Pharmaceuticals, the biotechnology company said yesterday.
Icoria will use its metabolomics platform to evaluate differences in treated and untreated animal subjects to identify biomarkers that Isis will use to suggest pathways for alteration by potential drug candidates, Icoria said.
Financial details were not disclosed.